Diabetes Mellitus, Heart Failure
Conditions
Keywords
High Protein Diet in heart failure, obesity and heart failure, Weight management in Heart failure, heart failure, diabetes and obesity
Brief summary
This research project was designed to study the role of dietary modifications in heart failure (HF) patients that suffer from type 2 diabetes mellitus and obesity. Specifically, the purpose of this study is to determine whether or not heart failure patients participating in a 3-month intensive lifestyle modification program of either a high protein (30 % of total calories from protein) group will have a significant improvement in weight reduction, quality of life and clinical outcomes compared to a standardized protein (15% of total calories from protein) group.
Detailed description
Clinical management of heart failure (HF) related to obesity and diet recommendations currently lacks a strong scientific basis, and clinicians are divided in their approach to diet recommendations for this patient population. It has been shown that in extremely obese HF patients, weight reduction improves cardiac structure and function as well as functional status and symptomatology. Evidence on the impact of voluntary weight loss on improvement in survival in obese HF patients, however, is limited. The purpose of this study is to determine whether or not heart failure patients participating in a 3-month intensive lifestyle modification program of either a high protein (30% of total calories from protein) group will have a significant improvement in weight reduction, quality of life and clinical outcomes compared to a standardized protein (15% of total calories from protein) group. In addition to dietary interventions, participants in both groups with be given an exercise prescription and encouraged to exercise for 20-30 minutes at least 3-5 times each week as tolerated. They will also continue to receive usual medical care, advice and other support for their condition from their cardiologist or medical physician. Both sets of participants will utilize self-monitoring tools to assist with diet compliance and behavior change. These self-monitoring tools are mandatory and will be collected and analyzed. At each visit, subjects will also be asked to will also be asked to have their weight and waist circumference measured and, at select visits, they will provide a 24 hour recall to assess fullness with the overall diet. Subjects will be given a 3-day food (3DFR) record at baseline, which will be returned at the the 2-week, 4- week and 8-week visits, and will also complete the 3DFR at three months.
Interventions
PROCEDURE12-week supervised weight loss intervention
Patients in the 2 study arms will participate in an intensive 12-week supervised weight loss intervention and will be seen by the same dietician at regular intervals: baseline, 2 weeks, 4 weeks, 8 weeks, and 12 weeks. Participants will receive personalized nutrition counseling and support during each of these visits. Participants will be randomized to either the HP or SP diet and assigned to receive one of two standard structured energy-restricted meal plans (1200, 1500 Kcal/day) based on the computed calorie deficit
Sponsors
University of California, Los Angeles
University of California, Irvine
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* obese (BMI \> 27 kg/m2); * history of type 2 DM or documented impaired fasting glucose (IFG) according to fasting plasma glucose levels of 100-125 mg/dl or meeting 3 out of 4 criteria or Metabolic Syndrome ( as defined by the International Diabetes Federation 2011 * evaluation of HF and optimization of medical therapy; and * ischemic or idiopathic HF etiology.
Exclusion criteria
* age ≤18 years old; * history of clinically significant illness including acute myocardial infarction or sustained ventricular arrhythmia in the prior 3 months or current liver, respiratory, and/or gastrointestinal disease and malignancy; * pregnancy or lactation; * serum creatinine level \> 1.5 mg/dl;\* * currently participating in a supervised weight loss program; * physician refusal to permit patient participation in the study; and * weight loss of \>6% in the last 6 months * gout or history of gout
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change from Baseline in adiposity (and body composition; i.e., % body fat)) | 3 months and 15 months |
Secondary
| Measure | Time frame |
|---|---|
| Change from Baseline in lipid profiles (while controlling for statin drug dosage) | 3 months and 15 months |
| Change from Baseline in glycemic control and insulin resistance | 3 months and 15 months |
| Change from Baseline in peripheral blood circulation (as measured using peripheral arterial tonometry and plasma nitroxide measurement) | 3 months and 15 months |
| Change from Baseline in levels of quality of life | 3 months and 15 months |
Other
| Measure | Time frame |
|---|---|
| Change in Cardiac Structure | 3 months and 15 months |
| Change in Cardiac Function | 3 months and 15 months |
Countries
United States
Outcome results
None listed